Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb to present immuno-oncology data at ASCO 2014

Bristol-Myers Squibb to present immuno-oncology data at ASCO 2014

6th May 2014

Bristol-Myers Squibb has announced that it will be sharing data on its latest immuno-oncology advances at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO).

The company will attend the Chicago event from May 30th to June 3rd 2014 to present findings on immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer and metastatic renal cell carcinoma.

Trial results for the investigational PD-1 immune-checkpoint inhibitor nivolumab will be highlighted in six oral presentations, including longer-term data from some trials that show the compound's efficacy in the treatment of melanoma.

Data will be used to highlight the efficacy of a proposed nivolumab/Yervoy combination for treating various cancers, while findings from a new Yervoy phase III melanoma trial will also be shared.

Francis Cuss, executive vice-president and chief scientific officer at Bristol-Myers Squibb, said: "We believe that immuno-oncology has the potential to be transformational in the treatment of cancer and to have broad applicability across multiple tumour types and lines of therapy."

Last week, the firm revealed that it generated $3.81 billion (2.25 billion pounds) in revenues during the first quarter of 2014. It also confirmed a deal to acquire iPierian, a privately-held biotechnology company.ADNFCR-8000103-ID-801717790-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.